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ABSTRACT
Background and Purpose: More than one-third of American adults are obese.
The prevalence of extreme obesity is rapidly rising. Nine medications are currently
approved for weight loss yet they remain under utilized with the focus primarily on
lifestyle modifications. The study’s objective was to determine current prescribing
patterns and attitudes of weight loss medications in the management of obesity among
primary care providers (PCPs).
Methods: PCPs were surveyed to determine practice patterns, attitudes, barriers,
and facilitators for prescribing weight loss medications.
Conclusions: A total of 105 surveys were completed. 76% of all PCPs did not
prescribe weight loss medications for long-term weight loss therapy and 58% of PCPs
had negative perceptions of pharmacotherapy as a treatment. Significant differences
existed between prescribing patterns and attitudes of advanced practice clinicians and
physicians. Safety concerns were identified as the greatest barrier. Having 2+
comorbidities and severe obesity were identified as facilitators for prescribing weight loss
medications. Under utilization of pharmacotherapy suggests that PCPs may not have
sufficient knowledge about medication safety profiles and efficacy. Delaying treatment
until patients have reached a high level of morbidity may be less efficacious than earlier
treatment.
Implications for Practice: Education regarding effectiveness and risks of weight
loss medications for obesity management is needed and earlier interventions with
pharmacotherapy may prevent significant morbidity and mortality.
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CHAPTER I: Introduction
Overview of the Research Problem
The prevalence of obesity in the United States (U.S.) is high. In 2011-2012, more
than one-third (35% or 78.6 million) of American adults were obese (Ogden, Carroll, Kit,
& Flegal, 2014). Although there have been no significant changes in obesity prevalence
since 2003-2004, the number of individuals living with obesity remains at an all-time
high. Furthermore, the prevalence of extreme obesity (body mass index [BMI] ≥40
kg/m2) increased by 70% between 2000 and 2010 (Sturm & Hattori, 2013). Obesity is a
substantial health concern, predisposing individuals to poor health outcomes caused by
associated co-morbidities.
Obesity substantially increases the risk of morbidity and mortality due to the wide
range of accompanying co-morbidities. According to the Centers for Disease Control
(CDC) obesity-related conditions comprise some of the leading causes of preventable
death, including cardiovascular disease, stroke, type 2 diabetes, and certain types of
cancer (CDC, 2016a). Overall, as BMI rises, the risk of multimorbidity (co-occurrence of
multiple long-term diseases) increases in both men and women. The prevalence of
multimorbidity in men and women with normal weight is 23% and 28% respectively,
rising to 44% in men and 51% in women with extreme obesity (Booth, Prevost, &
Gulliford, 2014). A weight loss of 5-10% of total baseline body weight can significantly
reduce cardiovascular disease risk factors, including lowering blood pressure and blood
cholesterol, as well as preventing or delaying the development of type 2 diabetes (CDC,
2016b).
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The direct and indirect costs attributed to obesity in the U.S. are staggering. While
direct medical costs may include prevention, diagnostic, and treatment services
associated with obesity and obesity-related diseases, indirect medical costs may include
premature mortality, higher disability insurance premiums, and productivity loss due to
obesity (Hammond & Levine, 2010). According to Finkelstein, Trogdon, Cohen, & Dietz
(2009), the estimated annual medical cost attributable to obesity in the U.S. was $147
billion. Overall, the annual medical burden of obesity has risen to almost 10 percent of all
medical spending. The medical spending for obese individuals across all payers is nearly
42%, or $1,429 higher than the spending for individuals who are normal-weight.
Similarly in 2006, medical spending for obese beneficiaries cost Medicare over $600 per
beneficiary per year more than normal-weight beneficiaries (Finkelstein et al., 2009).
Despite the concerning obesity epidemic, appropriate and consistent management
of obese individuals in primary care settings remains variable (Bleich, Pickett-Blakely, &
Cooper, 2011; Shiffman et al., 2009). Current clinical guidelines from the U.S.
Preventive Services Task Force recommend that all adult patients be screened for obesity
and individuals with BMI ≥30kg/m2 should be offered or referred to intensive,
multicomponent behavioral interventions (Moyer, 2012). Regardless of these
recommendations, several cross-sectional studies have shown that not only are obese
individuals not being consistently diagnosed, weight loss counseling by providers is also
infrequent, inconsistent, and sub-optimal (Bleich, 2011, Shiffman, 2009; Smith, 2011).
When weight loss counseling is incorporated into clinical practice, studies have found
that lifestyle interventions are the foundation of primary care provider’s (PCP’s)
counseling. Although pharmacotherapy and bariatric surgery are other available and
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effective weight loss interventions, they are often not included or rarely recommended to
individuals suffering from obesity (Ferrante, Piasecki, Ohman-Strickland, & Crabtree,
2009; Shiffman, 2009).
Lifestyle interventions alone are not particularly successful in providing longterm weight maintenance due to behavioral and environmental pressures as well as
biological mechanisms induced by weight loss (Korner & Aronne, 2003; Rosenbaum,
Hirsch, Gallagher, & Leibel, 2008). The addition of pharmacotherapy as an adjunct to
traditional diet and exercise approaches has shown to be an effective treatment option for
weight loss in obese individuals (Yanovski SZ & Yanovski JA, 2014). When combined
with lifestyle interventions, weight loss medications have resulted in 5-10% weight loss
(Gadde, 2011, Smith, 2010; Yanovski, 2014). While prior studies have examined factors
influencing and barriers preventing weight loss counseling in primary care settings, little
research has assessed PCPs’ practice patterns and attitudes around the use of weight loss
medications. There is lack of current research examining the underlying reasons for
limited pharmacotherapy use in weight loss counseling, despite its demonstrated efficacy.
Purpose of the Study
The purpose of this study was to examine prescribing patterns of currently
available, Food and Drug Administration (FDA) approved weight loss medications
among PCPs. A self-reported survey was used to evaluate prescribers’ current practice
patterns and attitudes around their use of weight loss medications in obesity management.
Theoretical Framework
The theoretical framework that guided this study was the Theory of Reasoned
Action (TRA) (Fishbein & Ajzen, 1975). The theory was developed in the late 1960s and
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later modified to the Theory of Planned Behavior. The relationship between beliefs,
attitudes, intentions, and behavior are explained by the TRA. Under this theory, it is
assumed that people are rational and make decisions based on available information. The
theory posits that behavior is predicted by the individual’s intention to perform the
behavior. In regards to the Theory of Planned Behavior, intention is the most important
element of a person’s behavior. Intention is the individual’s readiness to perform a
behavior as determined by their attitude toward the behavior, subjective norms, and
perceived control of the behavior.
An individual’s attitude is formed based on their overall evaluation of performing
the behavior and their beliefs about the behavior’s consequences. Attitude encompasses
knowledge, feelings, beliefs, intentions, and perceptions. Conversely, subjective norms
are the social pressures applied to an individual to perform or not perform a behavior.
These pressures may influence the decision to perform a behavior by an inherent desire to
conform to other’s opinions and to behave as others expect them to behave. Finally,
perceived behavioral control is the perceived power an individual has over performing
the behavior. Perceived control is influenced by the individual’s attitude and subjective
norms. Typically, the individual’s perceived control and thus intent to perform the
behavior will be greater if the attitude and subjective norm are positive.
The Theory of Reasoned Action helps explain providers’ behavior toward the use
of weight loss medications for obese individuals. This study encompasses the
components of this theory by assuming that providers’ intent to perform a behavior is
based on their beliefs, attitudes, subjective norms, and perceived control. The TRA is
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useful in determining the factors that predict a provider’s intentions to include
pharmacotherapy in obesity care.
Aims/Objective
The objective of the current study was to determine current prescribing patterns
and attitudes of weight loss medications in the management of obesity among PCPs. The
study had three aims including, 1.) To determine why PCPs are or are not including
weight loss medications in weight loss counseling, 2.) To determine what barriers exist
around the use of weight loss medications in obesity management, and 3.) To determine
under what circumstances PCPs are prescribing weight loss medications for obesity.
Nurse Practitioner Core Competencies
Nurse practitioners can play a significant role in producing positive health
outcomes for obese patients. As licensed independent practitioners, advanced practice
nurses provide leadership in the translation of new knowledge into practice (Thomas et
al., 2012). By seeking to better understand practice patterns and barriers regarding the use
of effective treatment options for the management of obesity, nurse practitioners can
implement the gained knowledge to provide improved and well-informed care to obese
patients. Furthermore, nurse practitioners are responsible as health care providers to
integrate ethical principles into their clinical decision-making (Thomas et al., 2012).
Thus, they are ethically accountable for recognizing and informing obese patients of all
available and effective treatment options. Nurse practitioners are in a position to be
leaders in transforming health care delivery and providing high quality care to patients
with complex conditions. Through this study, nurse practitioner core competencies were
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achieved by integrating new knowledge into the care of adults living with obesity and its
associated co-morbidities.
Significance
Understanding practice patterns, barriers, and PCP attitudes regarding the use of
weight loss medications for obesity management can identify knowledge gaps and inform
appropriate interventions for PCP education and training. Enhancing PCP skill and
knowledge around effective adjunct treatment options for obesity care may result in more
frequent pharmacotherapy use and thus greater long-term weight-loss maintenance and
improved patient outcomes. Additionally, the information gained from this study may be
helpful in the development and implementation of obesity treatment guidelines as they
expand to include more than traditional lifestyle and behavioral approaches to weight
loss.
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CHAPTER II: Comprehensive Literature Review
This chapter presents the available research related to current obesity management
practices, including the efficacy and use of available weight loss interventions.
Interventions currently included in weight loss counseling and efficacy
Available weight loss interventions include lifestyle modifications,
pharmacological approaches, and surgical options. Currently, lifestyle modifications
incorporating diet and physical activity remain the foundation of weight loss counseling
in primary care settings for patients who are overweight and obese.
Bleich et al. (2011) analyzed cross-sectional clinical encounter data from
physician office visits to identify whether obese patients received weight-related
counseling from their physician. Data on obese adults (n=2458) was obtained from the
National Ambulatory Medical Care Survey (NAMCS). Researchers found that a third of
the obese study sample received an obesity diagnosis, 17.6% received weight reduction
counseling, 20.5% received exercise counseling, and 25.2% received diet counseling.
Counseling about other weight loss interventions including obesity medication and
surgery was not studied. Likewise, Shiffman et al. (2009) conducted a cross-sectional
study evaluating what weight management interventions American adult patients
(n=3500) reported receiving from physicians. Data was collected through a random-digit
dialed telephone survey in 2005-2006. At the time of the study, 41.6% of respondents
were normal weight, 35.9% overweight, and 22.5% obese, according to BMI.
Respondents were asked a series of questions regarding the types of weight management
interventions physicians had ever recommended to them. Ten recommended interventions
were listed including being told about health problems associated with being overweight,
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changing their diet, suggesting diet and exercise, stating diet and exercise are the only
way to lose weight, prescribing weight loss medication, recommending over the counter
weight loss products, suggesting bariatric surgery, providing reading material about
weight loss, referral to dietitian/nutritionist, and suggesting a formal diet program.
Twenty-eight percent of respondents (14.1% of obese respondents) denied ever being
offered any of the listed interventions. The interventions most frequently reported
included having a physician tell them about health problems associated with being
overweight (48%) and suggesting diet and exercise (46.5%). Overall, only 4.0% of
respondents (9.8% of obese respondents) reported receiving a prescription for weight loss
medication. Bariatric surgery was recommended in 1.5% of participants. Both studies
were limited by their cross-sectional nature. Additionally, reports of weight loss
counseling were subjective and thus recall bias may have influenced study results by
under or over-estimating weight-related counseling.
While lifestyle modifications are recommended most frequently, diet and exercise
have not proven to be effective for long-term weight loss success. Although many
individuals are able to lose weight with diet, many go on to regain all or a majority of the
weight lost (MacLean, Bergouignan, Cornier, & Jackman, 2011).	
  Aside from behavioral
and environmental factors, neurohormonal mechanisms have been identified as promoters
of weight regain after weight loss caused by dietary restriction. In addition to reduced
energy expenditure, restricting calories results in compensatory changes in the peripheral
hormonal pathways including decreased levels of anorexogenic hormones, and increased
levels of ghrelin leading to increased appetite (Rosenbaum, Hirsch, Gallagher, & Leibel,
2008). The combination of decreased energy expenditure and changes in neurohormonal
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status leads to increased food intake, restoration of fat cell mass, and thus weight regain
(Korner & Aronne, 2003).
Physical activity alone produces only modest reduction in body weight. Donnelly,
Jacobsen, Heelan, Seip, & Smith (2000) studied the effects of continuous versus
intermittent exercise on body weight and composition for 18 months in moderately obese
females (n=22) who were previously sedentary. The continuous exercise group exercised
3 times per week for 30 minutes at 60-75% of maximal aerobic capacity. The intermittent
group walked briskly twice per day for 15 minutes each, 5 days per week. Overall,
weight loss was minimal in both weight groups. Participants in the continuous group
experienced a 2.1% decrease in weight from baseline compared to a 1.0% decrease in the
intermittent group. Due to the small sample size and sample limitation to women only
with moderate obesity, the study may not be generalizable to other populations. The
amount of weight loss seen in this study is comparable to a recent meta-analysis by
Thorogood et al. (2011) that evaluated the effect of isolated aerobic exercise programs on
weight loss in overweight and obese populations. In 14 randomized controlled trials
involving 1847 total subjects, researchers found that moderate-intensity aerobic exercise
programs of 6-12 months induced only a modest reduction in weight, averaging a
weighted mean difference of -1.6kg of weight loss for 6-month programs and -1.7 kg for
12-month programs. The results of the meta-analysis were limited by the lack of
homogeneity between the included studies. Differences in study populations and exercise
interventions may have provided inconsistent data, which could have altered the overall
weight reduction seen in the pooled analysis.
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Frequently recommended lifestyle modifications used in weight loss counseling
have shown only modest results. While exercise alone may not be an appropriate
intervention for significant weight reduction, dietary restriction often leads to weight
regain due to changes in energy expenditure and hormonal signals induced by weight
loss.
Weight loss counseling
Although assessment and management of obesity is indicated according to clinical
guidelines, many health care providers are not consistently recommending weight loss
interventions to all overweight and obese patients. Several studies have identified that
obesity care, including diagnosis varies depending on patient characteristics.
In the 2011 study by Bleich et al., a secondary aim was to identify physician,
sociodemographic, and clinical encounter characteristics associated with patients’
reception of an obesity diagnosis and weight-related counseling. Researchers found that
women, young adults aged 18-29, and severely/morbidly obese individuals were
significantly more likely to receive an obesity diagnosis. Individuals receiving an obesity
diagnosis were nearly 6 times more likely to receive weight-reduction counseling, nearly
3 times more likely to receive diet counseling, and 2.5 times more likely to receive
exercise counseling when compared to those without a formal obesity diagnosis.
Additional predictors of weight-loss counseling included seeing a cardiologist/other
internal medicine specialist, having a preventive visit, or more time spent with the
physician.
Dutton and colleagues (2014) examined the association between patient
characteristics, physician characteristics, and the physician-patient relationship and the
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likelihood of weight loss counseling by primary care physicians. The cross-sectional
study collected data through a self-reported survey of primary care patients (n = 143)
with obesity (mean BMI: 36.9kg/m2). Researchers found that a higher BMI (>35kg/m2),
more medical conditions, and having a female physician were associated with receiving
more frequent weight loss counseling. Frequency of physician visits and duration of
physician-patient relationship were not associated with the amount of weight loss
counseling received. Similarly, Simkin-Silverman et al. (2005) retrospectively examined
data from the Primary Care Weight Control Project to identify predictors of obesity
identification and weight control advice. Body mass index was a strong predictor of
receiving an obesity diagnosis. Factors associated with receiving weight control advice
included a history of type 2 diabetes, hypertension, high cholesterol, and arthritis,
patients’ readiness to change (preparation/action/maintenance), and number of past visits.
Body mass index and waist circumference were significant univariate predictors of
weight control advice, but no longer significant in multivariable models most likely
attributed to the variance associated with diabetes and other risk factors.
In summary, the literature regarding patient characteristics and predictors for
weight related counseling is inconsistent. Patient BMI, obesity co-morbidities, and
frequency of visits/time spent with the health care provider appear to be factors
associated with receipt of weight loss counseling in primary care settings. Understanding
predictors for weight management may influence intervention choice when providing
obesity care and management.
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Barriers to weight loss counseling
Several barriers have been identified in the literature regarding weight loss
counseling in primary care settings. Conversely, there was limited research examining
specific barriers related to prescribing weight loss medications. As both counseling and
prescribing pertain to obesity management, several barriers may in fact overlap.
Gunther, Guo, Sinfield, Rogers, and Baker (2012) conducted interviews with
general practitioners, practice nurses, and overweight or obese patients to explore barriers
for implementing specific guidelines in the management of adult obesity in general
practice. Health care provider barriers identified included a reluctance to take
responsibility for implementing obesity guidelines, lack of consistency in weight
management approaches across practices, lack of counseling skills, limited time with
patients, perceived lack of available services (psychological/nutritional), and restraints
imposed by commissioners of health. Huang et al. (2004) discussed barriers identified by
physicians in focus groups. Physician pessimism about patient’s desire and ability to lose
weight, pessimism about the effectiveness of weight loss counseling, lack of
comprehensive obesity management resources, insufficient time due to high patient
volume, underuse of dieticians or lack of experience working with dieticians, lack of skill
in providing brief counseling, and insufficient knowledge of best clinical practices were
recognized. The study found a significant barrier was physicians’ feelings of being
inadequately prepared to provide diet, exercise, and weight loss counseling. This suggests
that health care providers may have insufficient confidence, resources, and/or a lack of
knowledge regarding when medications might be indicated as well as their beneficial
effects.
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Forman-Hoffman, Little, and Wahls (2006) identified barriers to effectively
managing obesity in the Veteran’s Health Administration (VHA) primary care settings.
The most strongly related barrier to providing diet and exercise counseling was poor
obesity education during medical school and residency training. A lack of information
provided by the VHA to primary care clinicians and their patients regarding available
services for weight management was also perceived as a significant barrier. Additionally,
health care clinician attitudes may also be a barrier to weight loss counseling. For
example, the researchers also looked at whether clinicians counsel obese patients in a
positive or negative context. They found that clinicians who believe obesity is a disease
are more likely to counsel in a positive context compared to those who do not believe it is
a disease. Perceived barriers in the VHA may differ from other health care settings due to
differing policies, insurance coverage, and patient population. However, the study
findings provide insight that negative attitudes impact weight loss counseling and might
therefore influence intervention choice, including prescribing anti-obesity medication.
In summary, a wide range of barriers to weight loss counseling exists. Lack of
appropriate training, skills, and available resources was consistently demonstrated across
the literature. Barriers were associated with weight loss counseling as it pertained to diet
and exercise, and did not specifically include barriers around the use of pharmacologic
treatment options.
Available weight loss medications, efficacy, & safety
Nine medications are currently Food and Drug Administration (FDA) approved
for weight loss in the management of obesity. These agents are used as adjunct therapy to
lifestyle interventions and are typically reserved for individuals unable to lose weight
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with diet and physical activity alone and for those at greater health risk due to co-morbid
complications associated with obesity.
Pharmacotherapies approved for long-term therapy are classified based on their
targeted location of action. Centrally acting agents include lorcaserin (Belviq™),
phentermine/topiramate (Qsymia™), and buproprion/naltrexone (Contrave™,
Mysimba™). Peripherally acting agents include orlistat (Xenical™) and liraglutide
(Saxenda™). Four centrally acting amphetamine derivatives are also available for shortterm use (≤12 weeks) including phentermine, benzphetamine, phendimetrazine, and
diethylpropion. Differences between mechanisms of action exist between agents.
However, anti-obesity medications may interfere with the physiological mechanisms
induced by lifestyle interventions that promote weight gain and challenge long-term
maintenance. All agents produce their effects by reducing food intake or nutrient
absorption and/or increasing resting or activity-related energy expenditure (Jones &
Bloom, 2015).
Overall, anti-obesity medications have shown higher efficacy in producing weight
loss than lifestyle interventions alone. A review by Yanovski and Yanovski (2014) found
that long-term obesity medications produced significant weight loss when used in
combination with lifestyle modifications such as diet and exercise. Compared to placebo,
additional weight loss at 1 year ranged from approximately 3% of baseline weight with
orlistat and lorcaserin, to 9% with high-dose pherntermine/topiramate extended release
(ER). Several randomized controlled trials looking at anti-obesity drugs compared to
standard care have resulted in 5-10% weight loss when combined with lifestyle
interventions. For example, Gadde et al. (2011) assessed the efficacy of two doses of
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combined phentermine plus topiramate ER as an adjunct to diet and lifestyle modification
for weight loss in obese subjects (n=2487). Both doses resulted in greater efficacy
compared to placebo (lifestyle intervention alone). At least 5% weight loss was achieved
in only 21% of the placebo group compared to 62% of patients prescribed phentermine
7.5mg plus topiramate 46.0mg and 70% prescribed phentermine 15.0mg plus topiramate
92.0mg. Correspondingly, 7%, 37%, and 48% achieved ≥10% weight loss with the same
interventions. All groups received standardized counseling for diet and lifestyle
modification. The study was limited by its generalizability due to restriction of BMI (45
kg/m^2) and lack of ethnic (86% white) and gender (70% female) diversity.
As with all medications, anti-obesity agents can be accompanied by adverse
events. Several of the agents recently approved for long-term use (since 2012) have been
prescribed independently under other indications for many years and thus adverse side
effects have been well established. These medications include buproprion, naltrexone,
phentermine, topiramate, and liraglutide. In addition to studying efficacy, multiple
randomized controlled trials have included assessment of drug safety profiles. For
example, Smith et al. (2010) evaluated safety of lorcaserin as an outcome variable for
weight loss and maintenance, including rates of valvulopathy development. The rate of
cardiac valvulopathy was not increased among 2472 patients evaluated at year one and
1127 patients evaluated at year two. Its selective nature of serotonin 2C receptors is not
generally associated with the valvulopathy previously seen with serotonin 2B receptors,
although long-term data is not yet established.
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In summary, several randomized controlled trials have analyzed both safety and
efficacy of weight loss medications. They concluded that prescribing should be
individualized and based on a balance between risk and benefit profiles.
Current practice patterns around weight loss medication use
Few published studies that have examined weight loss counseling include the use
of weight loss medications. Ferrante, Piasecki, Ohman-Strickland, and Crabtree (2012)
studied family physicians’ practice patterns and attitudes regarding extremely obese
patients and associating factors, including physician knowledge and demographic
characteristics. Practicing family physicians (n =255) in New Jersey completed selfadministered surveys inquiring about knowledge regarding care of extremely obese
patients, weight management approaches, attitudes toward managing obesity, challenges
with physical examinations, availability of supplies, and strategies to improve care. The
most frequently recommended interventions included basic good nutrition/adding fruits
and vegetables (81.4% of physicians almost always recommended) and regular exercise
(79.2% of physicians almost always recommended). Conversely, 46.4% of respondents
reported almost never recommending weight loss drugs. Higher self-reported knowledge
about weight loss drugs was associated with more frequent weight loss drug
recommendations. Physicians with more than 7% of extremely obese patients in practice
were less likely to recommend weight loss medications compared to those with less than
7% of extremely obese patients. The self-reported nature of the study may have biased
results by over or underestimating practice patterns. Response bias may have also
impacted study findings, as responders may have been more interested in obesity than
those not responding; thus the results may not represent the general population.
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Glauser et al. (2015) explored the knowledge and practice patterns of primary
care physicians (PCPs), endocrinologists (ENDOs), cardiologists (CARDs) and
bariatricians (BARIs) regarding obesity screening and management. A random-sample of
300 United States-based practicing physicians completed case vignette surveys tailored to
their specialty. Self-reported demographic and practice information was also collected.
On average one-third of PCPs and CARDs’ patients were obese compared with 46% for
ENDOs and 75% for BARIs. Based on a case vignette presented to participants
describing an obese patient with multiple comorbidities and risk factors, BMI ≥30kg/m2
was the most selected indication for weight loss medication across all physician groups.
Expectations regarding the percentage of expected weight loss for a given case were
inconsistent. A considerable amount of physicians selected a 15% expected weight loss
(PCPs 32%, ENDOs 21%, CARDs 36%) with a serotonin 2c receptor agonist, which is
10% more than what has been demonstrated in the literature. All groups of physicians did
not perceive the available weight loss medications to be safe or effective. The cases were
not inclusive of all patient demographics, comorbidities, medical and personal histories
of which the physician may encounter in clinical practice and therefore may have altered
responses and study results. However, this suggests that physicians may lack the
necessary knowledge to effectively utilize weight loss agents in clinical practice.
In summary, studies that look at practice patterns related to pharmacological
interventions are limited. Within the available studies, the underlying influences around
prescribing weight loss medications have not been fully examined. Additionally, the
literature has focused primarily on physician prescribers and has not evaluated
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prescribing practices among other prescribers including physician assistants and nurse
practitioners.
Summary
Weight loss interventions include lifestyle modifications, pharmacotherapy, and
surgery. Currently, counseling in primary care settings is largely focused on lifestyle
modifications. Although a combination of diet and exercise may be an effective
intervention for initial weight loss, weight regain is prevalent and to some extent, a
function of internal homeostatic changes that stimulate appetite. While the majority of
studies have found that when health care providers do provide weight loss counseling to
obese patients, pharmacological approaches are rarely included with their typical
recommendations of diet and exercise. Five FDA approved weight loss medications have
demonstrated to be effective approaches to overcoming long-term challenges with weight
loss maintenance in obese individuals. While safety profiles of weight loss medications
have been a significant concern in the past, several of the new medications approved have
been used for many years under alternative indications and without serious adverse
events.
Current practice patterns around the use of weight loss counseling, including
patient characteristics associated with the initiation of counseling and barriers preventing
consistent counseling were examined in the literature review. While many of these
factors may be similar, limited research is available regarding the prescribing patterns of
anti-obesity medications. Four new agents have been FDA approved for long-term use
since 2012. With the high prevalence of obesity in America, it is essential that providers
are aware of all effective interventions for obesity management. Understanding provider
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practices and barriers around the use of these anti-obesity agents may provide insight
regarding why an effective addition to traditional lifestyle management is not frequently
recommended.
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Provider Attitudes and Practice Patterns of Obesity
Management with Pharmacotherapy
Abstract
Background and Purpose: More than one-third of American adults are obese.
The prevalence of extreme obesity is rapidly rising. Nine medications are currently
approved for weight loss yet they remain under utilized with the focus primarily on
lifestyle modifications. The study’s objective was to determine current prescribing
patterns and attitudes of weight loss medications in the management of obesity among
primary care providers (PCPs).
Methods: PCPs were surveyed to determine practice patterns, attitudes, barriers,
and facilitators for prescribing weight loss medications.
Conclusions: A total of 105 surveys were completed. 76% of all PCPs did not
prescribe weight loss medications for long-term weight loss therapy and 58% of PCPs
had negative perceptions of pharmacotherapy as a treatment. Significant differences
existed between prescribing patterns and attitudes of advanced practice clinicians and
physicians. Safety concerns were identified as the greatest barrier. Having 2+
comorbidities and severe obesity were identified as facilitators for prescribing weight loss
medications. Under utilization of pharmacotherapy suggests that PCPs may not have
sufficient knowledge about medication safety profiles and efficacy. Delaying treatment
until patients have reached a high level of morbidity may be less efficacious than earlier
treatment.
Implications for Practice: Education regarding effectiveness and risks of weight
loss medications for obesity management is needed and earlier interventions with
pharmacotherapy may prevent significant morbidity and mortality.
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Introduction
The prevalence of obesity in the United States (U.S.) is high. In 2011-2012, 35%,
or 78.6 million American adults were obese (Ogden, Carroll, Kit, & Flegal, 2014).
Although there have been no significant changes in obesity prevalence since 2003-2004,
those living with obesity remains at an all-time high. Alarmingly, the prevalence of
extreme obesity (body mass index [BMI] ≥40 kg/m2) increased by 70% between 2000
and 2010 (Sturm & Hattori, 2013).
The direct and indirect costs attributed to obesity in the U.S. are staggering. While
direct medical costs may include prevention, diagnostic, and treatment services
associated with obesity and obesity-related diseases, indirect medical costs may include
premature mortality, higher disability insurance premiums, and productivity loss due to
obesity (Hammond & Levine, 2010). According to Finkelstein, Trogdon, Cohen, & Dietz
(2009), the estimated annual medical cost attributable to obesity in the U.S. was $147
billion. Overall, the annual medical burden of obesity has risen to almost 10 percent of all
medical spending (Finkelstein et al., 2009).
Obesity is a significant health concern. The disease substantially increases the risk
of morbidity and mortality due to the wide range of associated co-morbidities. According
to the Centers for Disease Control (CDC), obesity-related conditions comprise some of
the leading causes of preventable death, including cardiovascular disease, stroke, type 2
diabetes, and certain types of cancer (CDC, 2016a). Overall, as BMI rises, the risk of
multi-morbidity (co-occurrence of multiple long-term diseases) increases in both men and
women. The prevalence of multi-morbidity in men and women with normal weight is
23% and 28% respectively, rising to 44% in men and 51% in women with extreme
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obesity (Booth, Prevost, & Gulliford, 2014). Weight loss of 5-10% of total baseline body
weight has been shown to decrease cardiovascular disease risk factors, including
lowering blood pressure and blood cholesterol, as well as preventing or delaying the
development of type 2 diabetes by reducing blood sugars (CDC, 2016b).
Despite the concerning obesity epidemic, appropriate and consistent management
of obese individuals in primary care settings remains varied (Bleich, 2011; Shiffman,
2009). Current clinical guidelines from the U.S. Preventive Services Task Force
recommend that all adult patients be screened for obesity and individuals with BMI
≥30kg/m2 should be offered or referred to intensive, multicomponent behavioral
interventions (Moyer, 2012). Regardless of these recommendations, several crosssectional studies have shown that not only are obese individuals not being consistently
diagnosed, weight loss counseling by primary care providers (PCPs) is also infrequent,
inconsistent, and sub-optimal (Bleich, 2011, Shiffman, 2009; Smith 2011). When weight
loss counseling is incorporated into clinical practice, studies have found that lifestyle
interventions are the foundation of PCP’s recommendations. Although pharmacotherapy
and bariatric surgery are available and effective weight loss interventions, they are often
not included or rarely recommended to individuals with obesity (Ferrante, 2012;
Shiffman, 2009).
Lifestyle interventions alone are not particularly successful in providing longterm weight maintenance due to behavioral and environmental pressures as well as
biological mechanisms induced by weight loss (Korner, 2003; Rosenbaum, 2008).
Although many individuals are able to lose weight initially with diet and exercise, more
than one-third of weight lost is regained within year one (MacLean, Bergouignan,
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Cornier, & Jackman, 2011).	
  The U.S. Food and Drug Administration (FDA) have
currently approved five medications for long-term weight loss therapy. The addition of
pharmacotherapy as an adjunct to traditional lifestyle approaches has shown to be an
effective treatment option for weight loss in obese individuals (Khera, 2016; Yanovski,
2014). When combined with lifestyle interventions, weight loss medications have
resulted in clinically significant weight loss of 5-10% (Gadde, 2011, Khera, 2016, Smith
2010; Yanovski, 2014).
Obesity management and weight loss counseling generally begin in the primary
care setting. While prior studies have examined factors influencing and barriers
preventing weight loss counseling in primary care, little research has assessed PCP’s
practice patterns and attitudes around the use of weight loss medications. There is lack of
current research examining the underlying reasons for limited pharmacotherapy use in
weight loss counseling, despite its demonstrated efficacy. Our objective was to determine
current prescribing patterns and attitudes of weight loss medications in the management
of obesity among PCPs. Our aims included 1.) To determine why PCPs are or are not
including weight loss medications in weight loss counseling, 2.) To determine what
barriers exist around the use of weight loss medications in obesity management, and 3.)
To determine under what circumstances PCPs are prescribing weight loss medications for
obesity.
Study design and methods
This study was reviewed and approved by the Internal Review Board prior to
study procedures. Inclusion criteria consisted of the ability to read and write in English,
self-identified as a PCP, and provided health care for individuals who are ≥18 years of
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age. Exclusion criteria included PCPs who provided patient care in specialty practices
that included bariatric health, endocrinology, and/or cardiology.
Data collection
A convenience sample of primary care nurse practitioners (NPs), physician
assistants (PAs), and physicians (MDs) were recruited using online list-serves from
regional professional organizations and on-site at one organization’s annual conference in
Northeastern, U.S. Potential participants during on-site data collection received a hard
copy invitation and survey and potential online participants received an electronic
invitation and survey. Participants’ completion of the distributed survey served as passive
informed consent. Data was entered into LimeSurvey statistical software (version 2.55).
Survey development
The study survey was formulated and adapted based on a review of the literature
reflecting current obesity management and barriers and facilitators for weight loss
counseling. Two content experts reviewed the survey to ensure clarity and content
validity. The survey contained 24 questions in which PCPs were asked to express their
impressions and use of obesity pharmacotherapy (Appendix B). Demographic data
including ethnicity, type of PCP (i.e. nurse practitioner, physician, or physician assistant),
years in practice, primary specialty, patient population, and location of clinical practice
were collected.
Analysis
PCP demographics were summarized using descriptive statistics and frequency
tables. Inferential statistics were computed to assess attitudes and practice patterns around
the use of weight loss medications. Pearson chi-square tests were computed to determine
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between group (physician vs. advanced practice clinician) differences in demographics,
attitudes, and practice patterns. McNemar tests were used to compare the recommended
use of each weight loss medication to its effectiveness. Open ended-questions were
transcribed using categorical data. For all analyses, a P-value of <0.05, two-sided, was
established as statistically significant. SPSS v. 23 was used for data analysis (IBM Corp,
2015).
Results
The survey reached approximately 964 PCPs. Of the nearly 964 PCPs
approached, 105 PCPs completed the survey, resulting in a response rate of
approximately 11%. Eleven of the respondents did not meet the study inclusion criteria,
resulting in a final n=94. The 94 respondents were self-identified as PCPs who worked
primarily in family practice, internal medicine, adult primary care, and women’s health.
The demographic and practice characteristics of the respondents are summarized in Table
1. Of the 94 respondents, 46 were MDs, 43 were NPs, and 5 were PAs. Due to the low
response rate of PAs, responses from NPs and PAs were combined to a single provider
group identified as advanced practice clinicians (APCs) (n=48).
Provider practice patterns around the use of weight loss medications for obesity
management
Overall, 60% of the PCPs surveyed reported not prescribing weight loss
medications for short-term weight loss therapy (<3 months). When grouped by provider
type, APCs (46%) were prescribing weight loss medication more frequently than MDs
(33%). 76% of PCPs reported not prescribing weight loss medications for long-term
therapy (≥3 months). Prescribing patterns were not statistically different between
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provider groups for long-term therapy. Recommended medications are outlined in Table
2 in order based on frequency of prescribing.
Provider attitudes of weight loss medications as a treatment for obesity
58% of all PCPs reported “negative” and “very negative” impressions of
pharmacotherapy as a treatment for obesity. 58% of APCs had a “neutral” to “very
positive” impression of weight loss medications compared to 20% of MDs (P=0.002).
75% of MDs had a negative impression. 4% of all PCPs felt weight loss medications
were safe. 52% of PCPs reported that some medications were safe and others were not
safe. 73% of APCs expected a >5% weight loss with the use of pharmacotherapy as an
adjunct to lifestyle interventions compared to 50% of MDs (P=0.044). Weight loss
medications perceived as effective are outlined in Table 2. While 40% of PCPs reported
recommending orlistat, only 19% of PCPs reported orlistat as being effective for weight
loss (Figure 1).
Perceived barriers to the use of weight loss medications
The most frequently reported factors preventing PCPs from prescribing weight
loss medications included fear of adverse events followed by fear of medication
interactions (Table 3). Cost and insurance coverage and lack of perceived effectiveness
were third. Lack of time was the least important barrier to prescribing. 60% of PCPs
reported that concern of medication adverse events was a barrier to prescribing weight
loss medications. 49% of PCPs reported that they would still not prescribe weight loss
medications even if cost and insurance coverage were not significant barriers. There was
a significant difference in responses between PCP types. 67% of APCs reported they
would prescribe if cost/insurance were not barriers, compared to 34% of MDs (P = 0.02).
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Perceived facilitators to the use of weight loss medications
The most frequently reported circumstance for recommending weight loss
medication was if patients had 2+ comorbidities associated with obesity. The second
most frequently reported circumstance was if patients had severe obesity (BMI ≥40
kg/m2) (Table 4). Failure to achieve goal weight with lifestyle interventions was third.
Mild obesity (BMI 30-34.9 kg/m2) was identified as the least important factor for
prescribing.
Discussion
Regardless of the high prevalence of obesity in the U.S. and its wide range of
associated co-morbidities, the PCPs in our study were hesitant to prescribe weight loss
medications, particularly for long-term therapy. In general, over half of the PCPs had an
overall unfavorable impression of pharmacotherapy as a treatment option for obesity,
with MDs having a more negative impression than APCs. This, in addition to safety
concerns and cost/insurance factors may explain why prescribing is low among all PCP
types.
Safety concerns were the most important barriers preventing PCPs from
prescribing weight loss medications. Although long-term safety data has not been
established for the combined agents approved for weight loss therapy, several drugs have
been prescribed independently for many years; thus adverse side effects have been well
established. Randomized controlled trials have examined drug efficacy and safety
profiles. Reported common adverse side effects included gastrointestinal upset,
neurological complaints (i.e. headache, dizziness, tremor; paresthesias), hypoglycemia,
and elevated heart rate (Yanovski, 2014; Khera, 2016). Serious adverse events were
	
  

27	
  

	
  

infrequently reported, comparable to placebo, varied depending on drug type, and
included conditions such as cholelithiasis, cholecystitis, pancreatitis, severe
hypoglycemia, and valvulopathy (Khera et al., 2016). Though long-term trials have not
been established, cardiac valvulopathy is generally associated with serotonin 2B receptor
medications as opposed to the more selective serotonin 2C receptor medications recently
approved (Smith et al., 2010). While weight loss medications may impose risk, obesity is
associated with significantly higher all-cause mortality relative to normal weight (Flegal,
Kit, Orpana, & Graubard, 2013). Thus, adverse effects of medications should be weighed
against the benefits seen with weight loss medications. The PCPs’ concerns about safety
in the current study support previous research findings where physicians did not perceive
available weight loss medications to be safe or effective (Glauser et al., 2015). This
suggests that PCPs may not have sufficient knowledge regarding the safety profiles of
available medication options. Education of PCPs regarding the drugs’ pharmacodynamics
as well as risks for adverse side effects may facilitate increased confidence for
prescribing, thus improving weight loss in obese patients.
Our results demonstrated that PCPs were more likely to prescribe weight loss
medications to patients who were severely obese than to patients who were moderately or
mildly obese. This is contrary to previous research, which found that physicians who
cared for >7% extremely obese patients were less likely to recommend weight loss
medications compared to those who cared for <7% extremely obese patients (Ferrante et
al., 2009). Conversely, although not specific to pharmacotherapy, our findings were
consistent with previous studies that have reported BMI as a key factor in providing
weight loss counseling to patients. Bleich et al. (2011) found that severely/morbidly
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obese individuals were significantly more likely to receive an obesity diagnosis and
therefore were nearly 6 times more likely to receive weight-reduction counseling than
those who did not receive a diagnosis. Dutton et al. (2014) also found that a higher BMI
(>35 kg/m2) was associated with receiving more frequent weight loss counseling.
According to our findings, it was evident that the degree of obesity was a pertinent factor
for prescribing medication. There was a direct relationship between weight severity and
increased prescribing. Obese patients who are not classified as severely obese may not be
receiving recommendations from their PCPs about all available and effective treatment
options, including pharmacotherapy. Further education of PCPs regarding when to
initiate conversations with patients about weight loss pharmacotherapy, to include all
levels of obesity, may lead to earlier interventions and prevention of worsening obesity
and co-morbid disease.
A modest 5-10% weight reduction has been shown to improve lipids, decrease
blood pressure, and reduce HbA1c in patients with obesity (Wing et al., 2011). A
systematic review showed that weight loss medications produced greater improvements
in cardiometabolic risk factors than behavioral interventions alone (Yanovski &
Yanovski, 2014). Other studies have shown that weight loss medications resulted in a
more pronounced improvement in blood pressure, lipids, and glycemic control when used
for patients with pre-existing co-morbid disease (Gadde, 2011). Weight loss medications
are approved for patients with a BMI of ≥30 kg/m2 or a BMI ≥ 27 kg/m2 with one or
more co-morbidity in conjunction with a reduced-calorie diet and increased physical
activity. The present study found that the most important facilitator for prescribing
weight loss medications was patients’ having two or more associated co-morbidities.
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These findings suggest that PCPs may be intervening too late, when patients have
reached the “severely obese” category and have already developed multiple comorbidities. Recommending and prescribing weight loss medications earlier in the
disease process may be a more proactive approach to preventing the long-term sequelae
of obesity.
Despite the overall low prescribing patterns for both short-term and long-term
weight loss therapy among all PCPs, APCs prescribed medication more frequently than
MDs and were significantly more likely to prescribe medication when cost and insurance
coverage were not pertinent factors. APCs also had a significantly more positive
impression of pharmacotherapy as a treatment for obesity and higher expectations for
weight loss than MDs. This suggests that PCPs with a higher expectation for weight loss
and more positive impression may be more likely to prescribe weight loss medications
for obesity. Previous research has shown that physicians’ higher self-reported knowledge
regarding weight loss medications was associated with fewer negative attitudes and more
frequent recommendations of pharmacotherapy options (Ferrante et al., 2009). With the
majority of the APC group being NPs, our findings may be attributable to the
philosophical lens of the nursing discipline. NPs traditionally take a holistic approach to
patient-centered, context-based, diagnostic reasoning and care planning that is in line
with nursing theory and philosophy (Burman, Stepans, Jansa, & Steiner, 2002).
Implementing a holistic approach that is patient-centered and highly individualized can
be key to producing positive outcomes for patients with obesity.
We found that PCPs continue to be reluctant to recommend weight loss
medications, despite their shown efficacy. Overall, anti-obesity medications have shown
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higher efficacy in producing weight loss than lifestyle interventions alone. A review by
Yanovski and Yanovski (2014) found that long-term obesity medications produced
significant weight loss when used in combination with lifestyle modifications such as diet
and exercise. Compared to placebo, additional weight loss at 1 year ranged from
approximately 3% of baseline weight to 9%. Similarly a systematic review by Khera et
al. (2016), found that all five medications approved for long-term weight loss therapy
achieved at least 5% weight loss at 52 weeks, a significant improvement in weight
maintenance.
Obesity management is multifactorial. Our study results suggest that obesity
management for many patients does not extend past behavioral counseling and
recommendations for diet and exercise. PCPs may not be appropriately educating their
patients about the full spectrum of available and effective treatment options for obesity
management. This may be due to low perceived effectiveness, safety concerns, and
specific patient characteristics required. When considering the Chronic Care Model
(Bodenheimer, Wagner, & Grumbach, 2002), patients cannot be fully informed and
engaged members in the decision-making process if they do not have fully informed and
engaged PCPs. This study demonstrates the need for increased educational programs for
PCPs regarding the indications, effectiveness, and potential risks associated with the use
of weight loss medications. Continuing education may enhance PCP knowledge about
weight loss medications and improve PCPs’ ability to have informed conversations with
patients and engage their patients in the decision-making process. Both PCPs and patients
need accurate information about treatment options to collaboratively weigh the risks with
the benefits. Additionally, earlier interventions with pharmacotherapy may prevent
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morbidity and mortality associated with obesity and its co-morbidities. Differences exist
in prescribing patterns between PCP types. Further research may be needed to better
understand these differences in PCP attitudes and prescribing patterns.
Limitations
The current study is primarily limited by the small sample size and low response
rate. Identifying list-serve numbers can be inexact; thus an exact response rate could not
be determined. Causal inferences could not be identified. PAs were not well represented
in the study. Future studies should examine the effect that educational programs, focused
on weight loss pharmacotherapy, have on PCP prescribing patterns.
Conclusion
This study demonstrates the need for supplementary educational programs to
cultivate informed PCPs about the safe and effective use of weight loss medications as a
component to obesity management. Educated PCPs can better inform and engage patients
in shared decision-making with regards to obesity management. The overarching goal of
PCPs is to reduce poor health outcomes and improve quality of life. Earlier use of
pharmacotherapy in combination with lifestyle modifications may reduce the costly
morbidity and mortality associated with obesity.
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Table 1: PCP demographic characteristics
Characteristic:
Respondents n (%):
Profession:
Nurse practitioner
43 (46)
Physician Assistant
5 (5)
Physician
46 (49)
Primary specialty:
Family Practice/Family Medicine
52 (56)
Internal Medicine
21 (23)
Adult Primary Care
11 (12)
Women’s Health
3 (3)
Other
6 (7)
Years in practice:
0-10
35 (37)
11-20
27 (29)
≥20
32 (34)
Practice type:
Solo
3 (4)
Group
44 (53)
Teaching hospital practice
36 (43)
Practice location:
Rural
36 (53)
Urban
32 (47)
% Of patient population ≥18 years old:
About 50%
3 (3)
Greater than 50%
88 (94)
Less than 50%
3 (3)
Average patient contact hours:
0-10
7 (8)
11-20
17 (18)
21-30
27 (29)
31-40
39 (43)
>40
2 (2)
Percent of patient population overweight/obese:
0-25%
2 (2)
26-50%
42 (45)
51-75%
43 (46)
76-100%
3 (3)
Race/ethnicity:
White
87 (93)
Black or African American
0 (0)
Hispanic or Latino
5 (5)
Asian
1 (1)
Native Hawaiian
0 (0)
American Indian
1 (1)
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Table 2: Recommended medications and perceived effectiveness
Medication
Orlistat
Phentermine
Phentermine/topiramate
Lorcaserin
Buproprion/naltrexone
Liraglutide
Diethylpropion
Benzphetamine
Phendimetrazine

	
  

Recommended (%)
40
30
27
12
12
9
2
0
0
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Perceived Effective (%)
19
21
33
13
21
13
1
2
0

	
  

Table 3: Important barriers to prescribing weight loss medications
Barrier
(Important)
Fear of adverse events
Fear of medication
interactions
Cost/insurance coverage
Lack of perceived
effectiveness
Lack of patient motivation
Insufficient knowledge about
available medication options
Insufficient knowledge about
current
guidelines/recommendations
Lack of available resources
for prescribing weight loss
medications
Lack of training & skill
related to overall obesity
management
Lack of time
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

PCPs
Combined
(n)
91
83

APCs (n)

MDs (n)

P value

47
45

44
38

0.963
0.322

78
78

41
34

37
44

0.346
0.001

72
68

40
38

32
30

0.104
0.042

62

35

27

0.156

53

29

24

0.198

44

28

16

0.007

22

14

8

0.107
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Table 4: Important facilitators for prescribing weight loss medications
Facilitator
(Important)
Patient has 2+ comorbidities associated
with obesity
Patient is severely obese
(BMI 40 kg/m2 or above)
Patient has failed to
achieve goal weight with
lifestyle interventions
alone
Patient requests
medication
Insurance coverage
Patient has 1 co-morbidity
associated with obesity
Patient is moderately
obese (BMI 35-39.9
kg/m2)
Patient is mildly obese
(BMI 30-34.9 kg/m2)

PCPs
APCs (n)
Combined
(n)
82
45

MDs (n)

P value

37

0.039

81

45

36

0.036

78

45

33

0.008

77

43

34

0.076

75
71

42
40

33
31

0.242
0.070

67

39

28

0.068

32

21

11

0.057
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Figure 1: Comparison of recommended medications and perceived effectiveness
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APPENDIX A
Research Information Sheet
Title of Study: Provider Attitudes and Practice Patterns of Obesity Management
with Pharmacotherapy
Principal Investigator (PI): Brittany Granara, RN
Faculty Sponsor: Dr. Jennifer Laurent, PhD, APRN
Funder: College of Nursing and Health Sciences
Introduction:
You are being invited to take part in this research study because you are a licensed,
practicing health care provider in the state of Vermont. This study is being conducted by
Brittany Granara, RN, in conjunction with Dr. Jennifer Laurent, PhD, APRN, at the
University of Vermont.
Purpose
The primary purpose of this study is to determine current prescribing patterns among
primary care providers of Food and Drug Administration (FDA) approved weight loss
medications in the management of obesity. The study has three aims including, 1.) To
determine why providers are or are not including weight loss medications in weight loss
counseling, 2.) To determine what barriers exist around the use of weight loss
medications in obesity management, and 3.) To determine under what circumstances
providers are prescribing weight loss medications for obesity.
Study Procedures
If you choose to take part in the study, you will be asked to complete a one-time pen and
paper and/or electronic survey. This survey is expected to take no longer than 10 minutes
to complete. Questions on the survey include demographic information, current
knowledge around available weight loss medications, current practice patterns around the
use of weight loss medications, and barriers preventing the use of weight loss
medications.
Some of the survey questions related to obesity pharmacotherapy may be familiar to you
and others may not. No judgments about individual practice competency or skill will be
made from the survey responses and there are no correct or incorrect answers to the
questions being asked.
Benefits
By participating in this current research study, there may not be any direct benefit for
you. However, information deemed from this study may benefit you and other health care
providers in the future.
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Risks
All data collected will not include personally identifying information in order to protect
your privacy.
Costs
No costs will be required of you for participating in this research study
Compensation
Should you choose to participate, you will receive a raffle ticket upon completion of the
survey to be entered into a lottery with your preferred contact information. One raffle
number at your conference will be selected to receive a $20 equivalent VISA gift card. If
you are completing the online electronic survey, an additional separate hyperlink will be
provided to you upon completion of the survey for you to enter your email information
into the online raffle.
Confidentiality
All personal demographic information collected about you throughout this study will be
kept anonymous and securely stored. No one will be capable of matching you to your
responses.
Voluntary Participation/Withdrawal
This research study is completely voluntary and you are not required to participate in this
survey. You are not required to complete every survey question to remain in the study,
and you may withdraw from the study at any point during the completion of the study.
Questions
If you have any questions about this study at any time, please contact me, Brittany
Granara, at the following phone number (802) 656-3024. If any questions or concerns
arise regarding your rights as a research participant, you may contact the Director of the
Research Protections Office at (802) 656-5040.
Participation
Participation in the study is voluntary. You may choose to not participate or withdraw
from the research at any time without discrimination and/or penalty.
Contact Information
Principal Investigator
Brittany Granara, RN
(802) 656-3024
bmnelson@uvm.edu
Faculty Sponsor
Dr. Jennifer Laurent, PhD, APRN
(802) 656-3024
Jennifer.Laurent@med.uvm.edu
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APPENDIX B
Research Survey
Title of Study: Provider Attitudes and Practice Patterns of Obesity Management with
Pharmacotherapy
Principle Investigator: Brittany Granara, RN
1. Do you see patients over the age of 18 years in your clinical practice?
a. Yes
b. No
2. Are you a primary care provider?
a. Yes
b. No
*If answered yes to questions 1-2, please proceed with survey. If no to either question 1
or 2, please stop here. Thank you for your time
3. What type of practitioner are you? (Please circle one)
a. Nurse Practitioner
b. Physician Assistant
c. Physician
4. What is your primary specialty? ________________
5. How many years have you practiced health care since completing your
educational requirements? ______________
6. Is greater than 50% of your clinical practice in primary care/internal medicine?
a. Yes
b. No
7. Please identify what statements best describe your practice
a. Solo practice
b. Group practice
c. Teaching hospital practice
d. Other: ____________
8.

What statement best describes your location of practice?
a. Rural
b. Urban
c. Other: ____________

9. Approximately, what percentage of your patient population is aged ≥18 years?
a. Approximately 50%
	
  

47	
  

	
  

b. Greater than 50%
c. Less than 50%
10. How many patient contact hours do you have per week? ____________
11. Do you currently care for patients who have obesity (BMI ≥30kg/m^2)?
a. Yes
b. No
c. Unknown
12. Approximately, what percentage of your population is overweight and/or obese?
a. 0-25%
b. 26-50%
c. 51-75%
d. 76-100%
13. What is your overall impression of pharmacotherapy as a treatment for obesity?
a. Very positive
b. Positive
c. Neutral
d. Negative
e. Very negative
f. Unknown- not familiar with pharmacotherapy for obesity
14. In your opinion, based on your clinical knowledge, currently available
medications for the treatment of obesity are:
a. Safe
b. Somewhat safe
c. Some medications are safe, others are not
d. Unsafe
15. Which, if any, medications have you recommended to a patient as a treatment for
obesity? (Check all that apply)
o Orlistat (Xenical™)
o Lorcaserin (Belviq™)
o Buproprion/naltrexone (Contrave™, Mysimba™)
o Phentermine/topiramate (Qsymia™)
o Liraglutide (Saxenda™)
o Phentermine
o Benzphetamine
o Phendimetrazine
o Diethylpropion
o Other (specify) _____________
16. Which, if any, medications do you think are effective for weight loss?
(Check all that apply)
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o
o
o
o
o
o
o
o
o
o

Orlistat (Xenical™)
Lorcaserin (Belviq™)
Buproprion/naltrexone (Contrave™, Mysimba™)
Phentermine/topiramate (Qsymia™)
Liraglutide (Saxenda™)
Phentermine
Benzphetamine
Phendimetrazine
Diethylpropion
Other (specify) _____________

17. How much weight loss would you expect your patients to achieve with
pharmacotherapy as an adjunct to lifestyle interventions?
a. 0-5%
b. 5-10%
c. 10-15%
d. >15%
e. Unknown
18. Please indicate whether or not the following factors would be important or not
important circumstances for recommending pharmacotherapy to your obese
patients? (Please check all- either important or not important)
Important Not
Important
o
o
Patient requests medication

	
  

o

o

Insurance coverage

o

o

Patient has failed to achieve goal weight with
lifestyle interventions alone

o

o

Patient is mildly obese (BMI 30-34.9 kg/m^2)

o

o

Patient is moderately obese (BMI 35-39.9
kg/m^2)

o

o

Patient is severely obese (BMI 40 kg/m^2 or
above)

o

o

Patient has 1 co-morbidity associated with
obesity (i.e. type II diabetes, hypertension,
hypercholesterolemia, arthritis, etc.)

o

o

Patient has 2+ co-morbidities associated with
obesity
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o

o

Other (please specify):___________________

19. Please indicate whether or not the following factors would be important or not
important factors in preventing you from prescribing pharmacotherapy as a
treatment for obesity? (Please check all- either important or not important):
Important Not
Important
o
o
Safety concerns- fear of adverse events
o

o

Fear of interaction with other medication

o

o

Cost/insurance coverage

o

o

Lack of perceived effectiveness

o

o

Insufficient knowledge about available
medication options

o

o

Insufficient knowledge about current
guidelines and recommendations

o

o

Lack of available resources for prescribing
weight loss medications

o

o

Lack of training and skill related to overall
obesity management

o

o

Lack of patient motivation

o

o

Lack of time

o

o

Other (please specify):___________________

20. If cost and insurance coverage were not barriers, would you then prescribe
pharmacotherapy as a treatment for obesity in addition to lifestyle modifications?
a. Yes
b. No
21. Is fear of adverse events preventing you from prescribing weight loss medications
to your obese patients?
a. Yes
b. No
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22. Do you currently prescribe weight loss medication for short-term weight loss
therapy (less than 3 months)?
a. Yes
b. No
23. Do you currently prescribe weight loss medication for long-term weight loss
therapy (≥ 3 months)?
a. Yes
b. No
24. What is your race/ethnicity? (Check all that apply)
o White
o Black or African American
o Hispanic or Latino
o Asian
o Native Hawaiian
o American Indian
o Other (specify):_______________
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